Roberts Chris-Tiann, Raabe Nicole, Wiegand Lara, Kadar Shahib Ashraf, Rastegar Mojgan
Department of Biochemistry and Medical Genetics, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB R3E 0J9, Canada.
Pharmaceuticals (Basel). 2024 Nov 27;17(12):1601. doi: 10.3390/ph17121601.
Metformin is a commonly used drug for treating type 2 diabetes. Metformin is an inexpensive drug with low/no side effects and is well tolerated in human patients of different ages. Recent therapeutic strategies for human disease have considered the benefits of drug repurposing. This includes the use of the anti-diabetic drug metformin. Accordingly, the anti-inflammatory, anti-cancer, anti-viral, neuroprotective, and cardioprotective potentials of metformin have deemed it a suitable candidate for treating a plethora of human diseases. As results from preclinical studies using cellular and animal model systems appear promising, clinical trials with metformin in the context of non-diabetes-related illnesses have been started. Here, we aim to provide a comprehensive overview of the therapeutic potential of metformin in different animal models of human disease and its suggested relationship to epigenetics and ailments with epigenetic components.
二甲双胍是一种常用的治疗2型糖尿病的药物。它价格低廉，副作用小/无副作用，不同年龄段的人类患者对其耐受性良好。人类疾病的最新治疗策略考虑了药物重新利用的益处。这包括使用抗糖尿病药物二甲双胍。因此，二甲双胍的抗炎、抗癌、抗病毒、神经保护和心脏保护潜力使其成为治疗多种人类疾病的合适候选药物。由于使用细胞和动物模型系统的临床前研究结果看起来很有前景，已开始在非糖尿病相关疾病的背景下进行二甲双胍的临床试验。在这里，我们旨在全面概述二甲双胍在不同人类疾病动物模型中的治疗潜力，及其与表观遗传学和具有表观遗传成分的疾病之间的潜在关系。
